{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:31:40Z","timestamp":1792625500050,"version":"4.5.0"},"reference-count":127,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In the year 2021, the universal definition and classification of heart failure (HF) was published that defines HF as a clinical syndrome with symptoms and\/or signs caused by a cardiac abnormality and corroborated by elevated natriuretic peptide levels or objective evidence of cardiogenic congestion. This definition and the classification of HF with reduced ejection fraction (HFrEF), mildly reduced, and HF with preserved ejection fraction (HFpEF) is consistent with the 2021 ESC Guidelines on HF. Among several other new recommendations, these guidelines give a Class I indication for the use of the sodium\u2013glucose co-transporter 2 (SGLT2) inhibitors dapagliflozin and empagliflozin in HFrEF patients. As the first evidence-based treatment for HFpEF, in the EMPEROR-Preserved trial, empagliflozin reduced the composite endpoint of cardiovascular death and HF hospitalizations. Several reports in 2021 have provided novel and detailed analyses of device and medical therapy in HF, especially regarding sacubitril\/valsartan, SGLT2 inhibitors, mineralocorticoid receptor antagonists, ferric carboxymaltose, soluble guanylate cyclase activators, and cardiac myosin activators. In patients hospitalized with COVID-19, acute HF and myocardial injury is quite frequent, whereas myocarditis and long-term damage to the heart are rather uncommon.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehab887","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T20:24:03Z","timestamp":1639513443000},"page":"367-376","source":"Crossref","is-referenced-by-count":28,"title":["The year in cardiovascular medicine 2021: heart failure and cardiomyopathies"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-117X","authenticated-orcid":false,"given":"Johann","family":"Bauersachs","sequence":"first","affiliation":[{"name":"Hannover Medical School Department of Cardiology and Angiology, , Carl-Neuberg-Stra\u00dfe 1, 30625 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-9140","authenticated-orcid":false,"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen Department of Cardiology, , Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Lindenfeld","sequence":"additional","affiliation":[{"name":"Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center , Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-0253","authenticated-orcid":false,"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[{"name":"Winters Center for Heart Failure, Cardiology, Baylor College of Medicine and Michael E. DeBakey VA Medical Center , Houston TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"2022102615081372900_ehab887-B1","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/eurheartj\/ehab068","article-title":"A call to action for new global approaches to cardiovascular disease drug solutions","volume":"42","author":"Figtree","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B3","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B4","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1093\/eurheartj\/ehab082","article-title":"The struggle towards a Universal Definition of Heart Failure\u2014how to proceed?","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B5","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ejhf.2143","article-title":"The heart failure association atlas: heart failure epidemiology and management statistics 2019","volume":"23","author":"Seferovic","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B6","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehaa1031","article-title":"Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank","volume":"42","author":"Wang","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B7","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/ejhf.2250","article-title":"Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy","volume":"23","author":"Restrepo-Cordoba","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B8","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1093\/eurheartj\/ehab325","article-title":"Statin associated lower cancer risk and related mortality in patients with heart failure","volume":"42","author":"Ren","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B9","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B10","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/eurheartj\/ehab241","article-title":"An automated computational image analysis pipeline for histological grading of cardiac allograft rejection","volume":"42","author":"Peyster","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/eurheartj\/ehaa841","article-title":"Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences","volume":"42","author":"Verdonschot","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B12","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/ejhf.2144","article-title":"Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction","volume":"23","author":"Woolley","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ehjdh\/ztaa015","article-title":"Artificial intelligence assessment for early detection of heart failure with preserved ejection fraction based on electrocardiographic features","volume":"2","author":"Kwon","year":"2021","journal-title":"Eur Heart J Digital Health"},{"key":"2022102615081372900_ehab887-B14","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1161\/CIRCULATIONAHA.120.053134","article-title":"Development and validation of machine learning-based race-specific models to predict 10-year risk of heart failure: a multicohort analysis","volume":"143","author":"Segar","year":"2021","journal-title":"Circulation"},{"key":"2022102615081372900_ehab887-B15","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/eurheartj\/ehab197","article-title":"Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies","volume":"42","author":"Hamdani","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B16","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/ejhf.2205","article-title":"Diagnostic recommendations and phenotyping for heart failure with preserved ejection fraction: knowing more and understanding less?","volume":"23","author":"Fraser","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B17","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ejhf.2201","article-title":"The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy \u2013 a multilevel assessment of myocardial fibrosis in dilated cardiomyopathy","volume":"23","author":"Raafs","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B18","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/eurheartj\/ehaa823","article-title":"Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction","volume":"42","author":"Sorimachi","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B19","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/eurheartj\/ehaa952","article-title":"Fighting HFpEF in women: taking aim at belly fat","volume":"42","author":"Withaar","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/eurheartj\/ehaa845","article-title":"Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations","volume":"42","author":"Assmus","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B21","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1093\/eurheartj\/ehab030","article-title":"Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23","volume":"42","author":"Garnier","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B22","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ejhf.2190","article-title":"Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ehjacc\/zuaa006","article-title":"The value of urinary sodium assessment in acute heart failure","volume":"10","author":"Tersalvi","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2022102615081372900_ehab887-B24","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/ehf2.13372","article-title":"Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge","volume":"8","author":"Biegus","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2022102615081372900_ehab887-B25","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1056\/NEJMoa2026845","article-title":"Milrinone as compared with dobutamine in the treatment of cardiogenic shock","volume":"385","author":"Mathew","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102615081372900_ehab887-B26","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/ehjacc\/zuab060","article-title":"Long-term 5-year outcome of the randomized IMPRESS in severe shock trial: percutaneous mechanical circulatory support vs. intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction","volume":"10","author":"Karami","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2022102615081372900_ehab887-B27","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1093\/eurheartj\/ehab110","article-title":"The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction","volume":"42","author":"Ceglarek","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B28","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S2213-2600(21)00172-7","article-title":"Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop","volume":"9","author":"Arrigo","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2022102615081372900_ehab887-B29","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/ejcts\/ezab018","article-title":"Five-year outcomes of patients supported with HeartMate 3: a single-centre experience","volume":"59","author":"Schmitto","year":"2021","journal-title":"Eur J Cardiothorac Surg"},{"key":"2022102615081372900_ehab887-B30","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1161\/CIRCULATIONAHA.121.055716","article-title":"Cerebrovascular events in patients with centrifugal\u2013flow left ventricular assist devices: a propensity score matched analysis from the intermacs registry","volume":"144","author":"Cho","year":"2021","journal-title":"Circulation"},{"key":"2022102615081372900_ehab887-B31","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/ejhf.2021","article-title":"Mechanical circulatory support does not reduce advanced myocardial fibrosis in patients with end-stage heart failure","volume":"23","author":"Kassner","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/ehjacc\/zuab029","article-title":"Prediction of right heart failure after left ventricular assist implantation: external validation of the EUROMACS right-sided heart failure risk score","volume":"10","author":"Rivas-Lasarte","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2022102615081372900_ehab887-B33","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jacc.2021.06.035","article-title":"Contemporary left ventricular assist device outcomes in an aging population: an STS INTERMACS analysis","volume":"78","author":"Emerson","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022102615081372900_ehab887-B34","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/CIRCULATIONAHA.120.049098","article-title":"Cell-free DNA to detect heart allograft acute rejection","volume":"143","author":"Agbor-Enoh","year":"2021","journal-title":"Circulation"},{"key":"2022102615081372900_ehab887-B35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ejhf.2133","article-title":"Risk stratification and management of women with cardiomyopathy\/heart failure planning pregnancy or presenting during\/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy","volume":"23","author":"Sliwa","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B36","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1093\/eurheartj\/ehaa455","article-title":"Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry","volume":"41","author":"Sliwa","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B37","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1002\/ehf2.13502","article-title":"Peripartum cardiomyopathy in Iraq: initial registry\u2013based data and 6 month outcomes","volume":"8","author":"Farhan","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2022102615081372900_ehab887-B38","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ehf2.13172","article-title":"Electrocardiographic features and their echocardiographic correlates in peripartum cardiomyopathy: results from the ESC EORP PPCM registry","volume":"8","author":"Mbakwem","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2022102615081372900_ehab887-B39","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2264","article-title":"Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry","author":"Jackson","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B40","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"2022102615081372900_ehab887-B41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/CIRCULATIONAHA.120.051968","article-title":"Gaps in evidence for risk stratification for sudden cardiac death in hypertrophic cardiomyopathy","volume":"143","author":"Pelliccia","year":"2021","journal-title":"Circulation"},{"key":"2022102615081372900_ehab887-B42","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/eurheartj\/ehab148","article-title":"Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy","volume":"42","author":"Marston","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B43","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","article-title":"Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK)","volume":"110","author":"Yilmaz","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2022102615081372900_ehab887-B44","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","author":"Herrmann","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B45","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study","volume":"42","author":"D\u2019Souza","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B46","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/eurheartj\/ehaa959","article-title":"Are we underestimating the potential for cardiotoxicity related to immune checkpoint inhibitors?","volume":"42","author":"Totzeck","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.120.053315","article-title":"From studying heart disease and cancer simultaneously to reverse cardio-oncology","volume":"144","author":"de Wit","year":"2021","journal-title":"Circulation"},{"key":"2022102615081372900_ehab887-B48","first-page":"ehab430","article-title":"Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy","author":"Michel","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B49","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2022102615081372900_ehab887-B50","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/ejhf.2029","article-title":"Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"de Boer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B51","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1093\/eurheartj\/ehab236","article-title":"What can heart failure trialists learn from oncology trialists?","volume":"42","author":"Zannad","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B52","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","article-title":"Heart failure drug treatment: the fantastic four","volume":"42","author":"Bauersachs","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B53","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.120.052926","article-title":"How should we sequence the treatments for heart failure and a reduced ejection fraction?: a redefinition of evidence-based medicine","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"2022102615081372900_ehab887-B54","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ejhf.2206","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Rosano","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B55","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1093\/eurheartj\/ehab054","article-title":"Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy\u2014analysis of registry data","volume":"42","author":"Porcher","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B56","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/ejhf.2259","article-title":"Effect of sacubitril\/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial","volume":"23","author":"Bhatt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B57","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1253\/circj.CJ-20-0854","article-title":"Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction-results from the PARALLEL-HF study","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J"},{"key":"2022102615081372900_ehab887-B58","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijcard.2021.01.061","article-title":"Real-world effectiveness and safety of sacubitril\/valsartan in heart failure: a systematic review","volume":"331","author":"Proudfoot","year":"2021","journal-title":"Int J Cardiol"},{"key":"2022102615081372900_ehab887-B59","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/ehf2.13547","article-title":"Sacubitril\/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis","volume":"8","author":"Giovinazzo","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2022102615081372900_ehab887-B60","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2020.11.071","article-title":"Sacubitril\/valsartan for the management of heart failure: a perspective viewpoint on current evidence","volume":"327","author":"Volpe","year":"2021","journal-title":"Int J Cardiol"},{"key":"2022102615081372900_ehab887-B61","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B62","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.121.054034","article-title":"Implantable cardioverter-defibrillator eligibility after initiation of sacubitril\/valsartan in chronic heart failure: insights From PROVE-HF","volume":"144","author":"Felker","year":"2021","journal-title":"Circulation"},{"key":"2022102615081372900_ehab887-B63","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1161\/CIRCULATIONAHA.121.054892","article-title":"Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction","volume":"144","author":"Docherty","year":"2021","journal-title":"Circulation"},{"key":"2022102615081372900_ehab887-B64","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ehf2.13137","article-title":"Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling","volume":"8","author":"Docherty","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2022102615081372900_ehab887-B65","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ejhf.2191","article-title":"Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics","volume":"23","author":"Jering","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B66","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ejhf.2277","article-title":"Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction","volume":"23","author":"Shah","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B67","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/eurheartj\/ehab057","article-title":"Quality of life in EMPEROR-Reduced: emphasizing what is important to patients while identifying strategies to support more patient-centred care","volume":"42","author":"Spertus","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B68","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"2022102615081372900_ehab887-B69","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehaa1007","article-title":"Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial","volume":"42","author":"Butler","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B70","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B71","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jchf.2020.04.008","article-title":"Effect of dapagliflozin in patients with HFrEF treated with sacubitril\/valsartan: the DAPA-HF trial","volume":"8","author":"Solomon","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2022102615081372900_ehab887-B72","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/eurheartj\/ehaa968","article-title":"Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","volume":"42","author":"Packer","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B73","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1093\/eurheartj\/ehab360","article-title":"Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","volume":"42","author":"Lam","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B74","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2337\/dc20-1675","article-title":"Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF","volume":"44","author":"Inzucchi","year":"2021","journal-title":"Diabetes Care"},{"key":"2022102615081372900_ehab887-B75","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/eurheartj\/ehz916","article-title":"The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context","volume":"42","author":"McMurray","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B76","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102615081372900_ehab887-B77","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium\u2013glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B78","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B79","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102615081372900_ehab887-B80","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ejhf.2137","article-title":"Sodium\u2013glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial","volume":"23","author":"Tromp","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B81","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurheartj\/ehab094","article-title":"Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial","volume":"42","author":"Heerspink","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B82","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102615081372900_ehab887-B83","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B84","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102615081372900_ehab887-B85","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B86","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/ejhf.2285","article-title":"Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial","volume":"23","author":"Ponikowski","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B87","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/ejhf.2221","article-title":"Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial","volume":"23","author":"Voors","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B88","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jacc.2021.04.065","article-title":"Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF","volume":"78","author":"Teerlink","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022102615081372900_ehab887-B89","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/eurheartj\/ehab234","article-title":"The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study","volume":"42","author":"Jankowska","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B90","first-page":"ehab411","article-title":"The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial","author":"Martens","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B91","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/ejhf.2253","article-title":"Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients","volume":"23","author":"Tkaczyszyn","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B92","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study","volume":"42","author":"T\u00e4ubel","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B93","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/eurheartj\/ehaa870","article-title":"CDR132L: another brick in the wall towards the use of miRNAs to treat cardiovascular disease","volume":"42","author":"Devaux","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B94","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/eurheartj\/ehaa967","article-title":"Antagonism of miRNA in heart failure: first evidence in human","volume":"42","author":"Baker","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B95","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ejhf.2082","article-title":"Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial","volume":"23","author":"Hazebroek","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B96","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1093\/eurheartj\/ehab569","article-title":"AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial","volume":"42","author":"Brignole","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B97","first-page":"euab232","article-title":"2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy","author":"Glikson","year":"2021","journal-title":"Europace"},{"key":"2022102615081372900_ehab887-B98","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ejhf.2046","article-title":"Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: A joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B99","first-page":"euab233","article-title":"Cardiac resynchronization therapy with or without defibrillator in patients with heart failure","author":"Schrage","year":"2021","journal-title":"Europace"},{"key":"2022102615081372900_ehab887-B100","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/j.jtcvs.2021.04.002","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"162","author":"Otto","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2022102615081372900_ehab887-B101","first-page":"ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","author":"Vahanian","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B102","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/eurheartj\/ehab086","article-title":"The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC","volume":"42","author":"Coats","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B103","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2020.12.047","article-title":"3-year outcomes of transcatheter mitral valve repair in patients with heart failure","volume":"77","author":"Mack","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022102615081372900_ehab887-B104","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/CIRCULATIONAHA.120.053061","article-title":"Relationship between residual mitral regurgitation and clinical and quality-of-life outcomes after transcatheter and medical treatments in heart failure: COAPT trial","volume":"144","author":"Kar","year":"2021","journal-title":"Circulation"},{"key":"2022102615081372900_ehab887-B105","doi-asserted-by":"crossref","first-page":"e010300","DOI":"10.1161\/CIRCINTERVENTIONS.120.010300","article-title":"Implications of atrial fibrillation on the mechanisms of mitral regurgitation and response to MitraClip in the COAPT trial","volume":"14","author":"Gertz","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"2022102615081372900_ehab887-B106","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1161\/CIRCULATIONAHA.120.049743","article-title":"Characteristics and outcome of COAPT-eligible patients in the MITRA-FR trial","volume":"142","author":"Iung","year":"2020","journal-title":"Circulation"},{"key":"2022102615081372900_ehab887-B107","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamacardio.2020.7200","article-title":"Association of effective regurgitation orifice area to left ventricular end-diastolic volume ratio with transcatheter mitral valve repair outcomes: a secondary analysis of the COAPT trial","volume":"6","author":"Lindenfeld","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2022102615081372900_ehab887-B108","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","article-title":"Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial","volume":"398","author":"Lindenfeld","year":"2021","journal-title":"Lancet"},{"key":"2022102615081372900_ehab887-B109","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ejhf.2033","article-title":"A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure","volume":"23","author":"Bekfani","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B110","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jacc.2021.01.030","article-title":"Cardiac rehabilitation for patients with heart failure: JACC expert panel","volume":"77","author":"Bozkurt","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022102615081372900_ehab887-B111","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2026141","article-title":"Physical rehabilitation for older patients hospitalized for heart failure","volume":"385","author":"Kitzman","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102615081372900_ehab887-B112","first-page":"330","article-title":"Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews","volume":"7","author":"Harrison","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2022102615081372900_ehab887-B113","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1002\/ehf2.13548","article-title":"Admission NT-proBNP and outcomes in patients without history of heart failure hospitalized with COVID-19","volume":"8","author":"Yoo","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2022102615081372900_ehab887-B114","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/ejhf.2096","article-title":"Circulating cardiovascular microRNAs in critically ill COVID-19 patients","volume":"23","author":"Garg","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102615081372900_ehab887-B115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ehf2.13061","article-title":"Insights into heart failure hospitalizations, management, and services during and beyond COVID-19","volume":"8","author":"Charman","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2022102615081372900_ehab887-B116","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/eurheartj\/ehab028","article-title":"All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study","volume":"42","author":"Butt","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102615081372900_ehab887-B117","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(21)00214-9","article-title":"Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial","volume":"9","author":"Bauer","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2022102615081372900_ehab887-B118","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial","volume":"325","author":"Lopes","year":"2021","journal-title":"JAMA"},{"key":"2022102615081372900_ehab887-B119","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","article-title":"Continuation versus discontinuation of renin\u2013angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial","volume":"9","author":"Cohen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2022102615081372900_ehab887-B120","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022102615081372900_ehab887-B121","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","article-title":"Myocarditis with COVID-19 mRNA vaccines","volume":"144","author":"Bozkurt","year":"2021","journal-title":"Circulation"},{"key":"2022102615081372900_ehab887-B122","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0140-6736(20)32656-8","article-title":"6-month consequences of COVID-19 in patients discharged from hospital: a cohort study","volume":"397","author":"Huang","year":"2021","journal-title":"Lancet"},{"key":"2022102615081372900_ehab887-B123","first-page":"116","article-title":"Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection","volume":"6","author":"Rajpal","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2022102615081372900_ehab887-B124","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1161\/CIRCULATIONAHA.120.052573","article-title":"COVID-19 myocardial pathology evaluation in athletes with cardiac magnetic resonance (COMPETE CMR)","volume":"143","author":"Clark","year":"2021","journal-title":"Circulation"},{"key":"2022102615081372900_ehab887-B125","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamacardio.2021.0565","article-title":"Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening","volume":"6","author":"Martinez","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2022102615081372900_ehab887-B126","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2020.11.031","article-title":"Pathological evidence for SARS-CoV-2 as a cause of myocarditis: JACC review topic of the week","volume":"77","author":"Kawakami","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022102615081372900_ehab887-B127","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1093\/eurheartj\/ehab075","article-title":"Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance","volume":"42","author":"Kotecha","year":"2021","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/5\/367\/46646059\/ehab887.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/5\/367\/46646059\/ehab887.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T15:42:22Z","timestamp":1666798942000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/5\/367\/6491391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":127,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,1,3]]},"published-print":{"date-parts":[[2022,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab887","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2022,1,3]]}}}